Search Results
252 items found for "Keltic Pharma Therapeutics"
- GPCR Updates: Celebrating Breakthroughs, New Course Launches Soon, and Exclusive Discounts! | Aug 26 - Sep 1, 2024
Discovery on Target’s 19th Annual GPCR-Based Drug Discovery Targeting G Protein-Coupled Receptors for New Therapeutic Modalities A quick revision of how β-adrenergic receptors work and how their antagonists can achieve therapeutic Galien USA ‘Best Startup’ Award: Pioneering GPCR-Driven Immunotherapies in Cancer Treatment Structure Therapeutics
- 📰 GPCR Weekly News, February 20 to 26, 2023
Allosteric modulation of conserved motifs and helices in 5HT2BR: Advances drug discovery and therapeutic GPCRs in Cardiology, Endocrinology, and Taste α1-Adrenergic Receptors: Insights into Potential Therapeutic Industry News Josephine (Pina) Cardarelli from GPCR Therapeutics on Beyond Biotech Podcast Crinetics
- Molecular insights into psychedelic drug action
actions and suggest that these discoveries can facilitate new insights into their hallucinogenic and therapeutic
- Molecular targets of psychedelic-induced plasticity
toward exploring the relationship between the actual psychedelic effects and those manifestations of therapeutic
- Angiotensin-(1-7) improves cognitive function and reduces inflammation in mice following mild trauma
This study examined the therapeutic effect of Ang-(1-7) on secondary injury observed in a murine model
- G protein-coupled receptor signaling: transducers and effectors
physiological functions and in a large number of Food and Drug Administration (FDA)-approved drugs as therapeutic
- Jan Steyaert Named 2022 Jacob and Louise Gabbay Award Winner
combination of Steyaert’s fundamental research and his ability to apply the research to the development of therapeutic
- Class B1 GPCR Dimerization: Unveiling Its Role in Receptor Function and Signaling
only enhances our understanding of class B1 GPCR biology but also opens new avenues for developing therapeutic Graaf, C., et al., Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic
- G protein-coupled receptor interactions and modification of signalling involving the ghrelin ...
The growth hormone secretagogue receptor 1a (GHSR1a) is intriguing because of its potential as a therapeutic Initial studies of the receptor focused on the potential therapeutic ability for growth hormone (GH)
- Molecular basis for ligand modulation of the cannabinoid CB 1 receptor
These advances have paved the way for development of novel ligands for different therapeutic applications
- 📰 GPCR Weekly News, April 1 to 7, 2024
signaling in humoral immunity Industry News Neurosterix launches with $63M to Advance Allosteric Modulator Therapeutics Financial Resultsand Confirms Its 2024 Outlook Sosei Heptares officially changed their name to Nxera Domain Therapeutics
- Expression pattern and clinical significance of beta 2-adrenergic receptor in oral squamous cell...
2-adrenergic receptor in oral squamous cell carcinoma: an emerging prognostic indicator and future therapeutic
- Crinetics Pharmaceuticals Expands Executive Team With Appointment Of James Hassard As Chief ...
stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics
- Viral G Protein-Coupled Receptors Encoded by β- and γ-Herpesviruses
Finally, we briefly discuss the therapeutic targeting of vGPCRs as future treatment of acute and chronic
- Reversible Photocontrol of Dopaminergic Transmission in Wild-Type Animals
animals and opens the way to remotely controlling dopaminergic neurotransmission for fundamental and therapeutic
- Exploring pharmacological inhibition of G q/11 as an analgesic strategy
These can be used either as stand-alone therapeutics or to improve the safety profile of opioid drugs
- Structures of oxysterol sensor EBI2/GPR183, a key regulator of the immune response
new insight into how EBI2 is activated by an oxysterol ligand and will facilitate the development of therapeutic
- Activation of the human chemokine receptor CX3CR1 regulated by cholesterol
receptor subfamily, CX3CR1 binds to its sole endogenous ligand CX3CL1, which shows notable potential as a therapeutic
- Isoform-and ligand-specific modulation of adhesion GPCR ADGRL3/Latrophilin3 by a synthetic binder
using unique tools, and thus establishes a foundation for the development of fine-tuned aGPCR-targeted therapeutics
- Crinetics Pharmaceuticals Announces Pricing Of Underwritten Common Stock Offering
clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics
- 📰 GPCR Weekly News, March 27 to April 4, 2023
Therapeutic potential of opioid receptor heteromers in chronic pain and associated comorbidities. Industry News Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover SMILES-based de novo molecular generation with curriculum and deep reinforcement learning Structure Therapeutics
- 📰 GPCR Weekly News, May 22 to 28, 2023
Therapeutic antagonism of the neurokinin 1 receptor in endosomes provides sustained pain relief. Patients with Idiopathic Pulmonary Fibrosis Exscientia Business Update for First Quarter 2023 Structure Therapeutics
- Chronic itch: emerging treatments following new research concepts
itch processing, the numerous mediators and receptors involved has led to a large variety of possible therapeutic
- Orion Announces The Rapid Lead Optimization Of Ob-004 - A Ccr2 Antagonist
Ottawa, Ontario, Canada, Nov. 30, 2021 -- Orion Biotechnology , a clinical stage company unlocking the therapeutic
- Extracellular signal-regulated kinases – a potential pathway for GPCR-targeted drug discovery
In summary, targeting GPCR-activated ERK pathways represents a promising strategy for developing new therapeutics ERK-dependent apoptosis as a potential therapeutic strategy for cancer. Cells, 10(10), 2509.
- A central alarm system that gates multi-sensory innate threat cues to the amygdala
The identification of unified innate threat pathways may provide insights into developing therapeutic
- 📰 GPCR Weekly News, July 17 to July 23, 2023
GPCR Symposium on GPCRs as Therapeutic Modalities on September 22nd. Domain Therapeutics announces the European Patent Office decision to grant a patent for its proprietary
- Nanobodies as Probes and Modulators of Cardiovascular G Protein-Coupled Receptors
nanobodies with tailored specificities may expand the impact of these tools for both basic science and therapeutic